CBD Summit Identifies a Course of Action

CBD Summit Identifies a Course of ActionCBD Summit Identifies a Course of Action

On Wednesday, the Collaborative for CBD Science and Safety hosted “The CBD Summit: A National Dialogue on Public Safety, Research, and Policy” in Washington, D.C. The Collaborative is comprised of several national entities including the Council for Responsible Nutrition, the Food and Drug Law Institute, the Alliance for the Adoption of Innovations in Medicine, and NACBHDD, among others. The venue was packed to capacity, with more than 140 in attendance. Participants represented the federal government and the research, business, not-for-profit and consumer communities. The purpose of the Summit was to take stock of our current knowledge and practice around CBD (cannabidiol) as a medicine and CBD as a food supplement or cosmetic, and then to begin to plot a course forward. Today, we are in a phase that many would describe as the “CBD craze” in which wild claims— without evidence—are made about the medicinal effects of CBD for a broad array of illnesses. To date, only one CBD formulation—Epidiolex—has been approved by the Food and Drug Administration (FDA) as a medicine for refractory epilepsy in small children. However, many companies sell over-the-counter CBD salves, oils, tablets, gummies and water products without evidence of their safety or efficacy. Consumers lack knowledge about this dizzying array of choices available in the market. Morning speakers at the summit documented that research lags far, far behind marketing around CBD. There are more than 120 known cannabinoids, and most have not been the subject of any research. The FDA has yet to define pathways for ...
More on: www.psychcongress.com